BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 30551078)

  • 1. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
    Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
    Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
    Santoni M; Conti A; Procopio G; Porta C; Ibrahim T; Barni S; Guida FM; Fontana A; Berruti A; Berardi R; Massari F; Vincenzi B; Ortega C; Ottaviani D; Carteni G; Lanzetta G; De Lisi D; Silvestris N; Satolli MA; Collovà E; Russo A; Badalamenti G; Luzi Fedeli S; Tanca FM; Adamo V; Maiello E; Sabbatini R; Felici A; Cinieri S; Montironi R; Bracarda S; Tonini G; Cascinu S; Santini D
    J Exp Clin Cancer Res; 2015 Feb; 34(1):10. PubMed ID: 25651794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
    Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical characteristics and prognosis of renal cell carcinoma patients with bone metastases].
    Zhai JP; Liu N; Wang H; Wang HD; Man LB
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(14):1068-1071. PubMed ID: 32294868
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcomes of 168 Chinese patients after local surgery for bone metastases arising from advanced renal cell carcinoma.
    Dong Y; Wang Z; Lu X; Wu Z; Zhang Z; Yu Y; Peng F; Liu B; Wang L
    Cancer; 2020 May; 126 Suppl 9():2079-2085. PubMed ID: 32293722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
    Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
    Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis.
    Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
    Urol Oncol; 2016 Oct; 34(10):433.e1-8. PubMed ID: 27321354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.
    Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
    J Neurooncol; 2016 Oct; 130(1):221-228. PubMed ID: 27538910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
    Kalra S; Verma J; Atkinson BJ; Matin SF; Wood CG; Karam JA; Lin SH; Satcher RL; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
    Clin Genitourin Cancer; 2017 Jun; 15(3):363-370. PubMed ID: 28216278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
    Gravis G; Chanez B; Derosa L; Beuselinck B; Barthelemy P; Laguerre B; Brachet PE; Joly F; Escudier B; Harrison DJ; Laird A; Vasudev N; Ralph C; Larkin J; Lote H; Salem N; Walz J; Thomassin J; Sfumato P; Stewart GD; Boher JM;
    Urol Oncol; 2016 Apr; 34(4):167.e17-23. PubMed ID: 26670200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Prognosis of Renal Cell Carcinoma With Spinal Bone Metastases.
    Zhai J; Liu N; Wang H; Huang G; Man L
    Front Oncol; 2021; 11():659779. PubMed ID: 34221976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating patients with renal cell carcinoma and bone metastases.
    Guida A; Escudier B; Albiges L
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1135-1143. PubMed ID: 30183421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis.
    Yuasa T; Urakami S; Yamamoto S; Yonese J; Saito K; Takahashi S; Hatake K; Fukui I
    Clin Exp Metastasis; 2011 Apr; 28(4):405-11. PubMed ID: 21365325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
    Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
    PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
    De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
    Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
    Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
    J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
    Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
    Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
    McKay RR; Kroeger N; Xie W; Lee JL; Knox JJ; Bjarnason GA; MacKenzie MJ; Wood L; Srinivas S; Vaishampayan UN; Rha SY; Pal SK; Donskov F; Tantravahi SK; Rini BI; Heng DY; Choueiri TK
    Eur Urol; 2014 Mar; 65(3):577-84. PubMed ID: 23962746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical study of brain metastasis of renal cell carcinoma.
    Harada Y; Nonomura N; Kondo M; Nishimura K; Takahara S; Miki T; Okuyama A
    Eur Urol; 1999 Sep; 36(3):230-5. PubMed ID: 10450008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.